secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0001437749-24-010427
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen enrolls first patient in PALISADE-3 Phase 3 fasedienol trial for social anxiety disorder
--------------------------------------------------------------------------------

- PALISADE-3 is a randomized, double-blind, placebo-controlled study of ~236 adults aged 18–65 with SAD.
- Primary endpoint is patient-rated SUDS; patients randomized 1:1 to fasedienol or placebo.
- Follows positive PALISADE-2 results; PALISADE-4 replication planned for H2 2024.
- Social anxiety disorder affects over 25 million Americans; fasedienol is an investigational pherine.
- CEO Shawn Singh calls the initiation a 'major milestone' toward first-in-class treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000143774924010427/0001437749-24-010427-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000143774924010427/vtgn20240401_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-010427

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer